PRECOSE
LOE ApproachingNDAORALTABLET
Approved
Sep 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
PRECOSE by Bayer is mechanism of action: in contrast to sulfonylureas, precose does not enhance insulin secretion. First approved in 1995.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PRECOSE (acarbose) is an oral small-molecule alpha-glucosidase inhibitor approved in 1995 for type 2 diabetes management. It works by competitively inhibiting pancreatic and intestinal enzymes that break down complex carbohydrates, thereby delaying glucose absorption and reducing postprandial hyperglycemia. Unlike sulfonylureas, acarbose does not stimulate insulin secretion and has additive glycemic control effects when combined with other diabetes agents.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure; team focus likely shifting toward cost management and retention strategies rather than growth initiatives.
Mechanism of Action
Mechanism of Action: In contrast to sulfonylureas, PRECOSE does not enhance insulin secretion. The antihyperglycemic action of acarbose results from a competitive, reversible inhibition of pancreatic alpha-amylase and membrane-bound intestinal alpha-glucoside hydrolase enzymes. Pancreatic…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PRECOSE offers stable but limited growth potential; this is a mature, commoditized product best suited for professionals with expertise in managed care economics, generic competition dynamics, and cost-containment strategy. Career value lies in gaining experience managing legacy brands through LOE and post-LOE phases, not in building high-growth commercial platforms.
Worked on PRECOSE at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.